Guidelines on disease-modifying treatment in MS: a decade-long update

The latest guidelines on disease-modifying treatment in multiple sclerosis (MS) from the Association of British Neurologists is discussed in this intercontinental podcast with perspectives from the UK, the USA, and Australia.   Participants: <ul> <li>Professor Alasdair Coles is Head of Department for Clinical Neuroscience and also Co-Director of the Cambridge Centre for Myelin Repair, UK.</li> <li>Dr. Tamara Kaplan is Assistant Professor of Neurology at Harvard Medical School, and is also affiliated with the Brigham and Women's Hospital, Boston, USA.</li> <li>Professor Michael Barnett is a consultant neurologist at Royal Prince Alfred Hospital Sydney, Central Clinical School, and Director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre, University of Sydney, Australia.</li> </ul> Read the <a href='https://pn.bmj.com/content/25/1/18'>paper</a> (<a href='https://pn.bmj.com/content/25/1/18'>https://pn.bmj.com/content/25/1/18</a>) which is part of the Fe...